Experts foresee premium pricing for overdose-fighting injector Evzio

Tracy Staton

Amid fierce debate over hepatitis C drug costs, another example of potentially questionable looms, The New York Times contends. The new anti-overdose , , is as-yet unpriced, but it could well follow in the footsteps of other newly approved–and newly pricey–formulations of long-off-patent meds.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS